AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33957195 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% Ruxolitinib cream
Number of subjects: 1249
Study 33957195 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1249
Study 36223695 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab into the thigh
Number of subjects: 219
Study 36223695 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous trastuzumab into the abdominal wall (AW)
Number of subjects: 219
Study 34170392 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant dextrin (14 g/day NUTRIOSE® FB06)
Number of subjects: 36
Study 34170392 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 36
Study 32630031 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy (5‐methyl‐tetrahydrofolate: 15 mg/day)
Number of subjects: 32
Study 32630031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/day of Oxo with 300 μg folic acid (oxifolic)
Number of subjects: 32
Study 32630031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/day of Oxo alone (magnesio+)
Number of subjects: 32
Study 36141878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasos Para Prevenir Cancer (PPPC) program
Number of subjects: 209
Study 33821693 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg intravenous Q4W
Number of subjects: 290
Study 33821693 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg subcutaneous Q4W
Number of subjects: 290
Study 33821693 — intervention group
Group type: COMPARATOR
Intervention: 300 mg intravenous Q12W
Number of subjects: 290
Study 33821693 — intervention group
Group type: COMPARATOR
Intervention: 300 mg subcutaneous Q12W
Number of subjects: 290
Study 33821693 — intervention group
Group type: COMPARATOR
Intervention: 150 mg intravenous Q12W
Number of subjects: 290
Study 33821693 — intervention group
Group type: COMPARATOR
Intervention: 150 mg subcutaneous Q12W
Number of subjects: 290
Study 32584979 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE screening (10-year fatal and non-fatal risk)
Number of subjects: 14478
Study 32584979 — intervention group
Group type: COMPARATOR
Intervention: CAC scoring
Number of subjects: 14478
Study 35907900 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE digital intervention (comprising a preparatory one‐to‐one session, six fortnightly online group sessions, and 12 weekly self‐directed website sessions)
Number of subjects: 60
Study 35907900 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE digital intervention
Number of subjects: 60
Study 34609773 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin plus chemotherapy (temozolomide) in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Number of subjects: 53
Study 34609773 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin alone in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Number of subjects: 53
Study 34609773 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin plus chemoradiotherapy in first-line therapy for newly diagnosed WHO grade III/IV glioma
Number of subjects: 53
Study 34609773 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin alone or plus chemotherapy/chemoradiotherapy
Number of subjects: 53
Study 34144507 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 110
Study 34144507 — intervention group
Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 110
Study 32028023 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% minoxidil gel
Number of subjects: 62
Study 32028023 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.2% glyceryl trinitrate (GTN) cream
Number of subjects: 62
Study 34231044 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphyseal anchoring short stem
Number of subjects: 18
Study 34231044 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened straight stem
Number of subjects: 18
Study 34231044 — intervention group
Group type: COMPARATOR
Intervention: Straight stem
Number of subjects: 18
Study 34058422 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 342
Study 75134022 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback assisted deep muscle relaxation training
Number of subjects: 0
Study 75134022 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 0
Study 34455583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (700 mg, 2,800 mg, or 7,000 mg)
Number of subjects: 24
Study 34455583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32843370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release
Number of subjects: 48
Study 32843370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34971025 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach Pepper (humanoid SAR system)
Number of subjects: 32
Study 34971025 — intervention group
Group type: COMPARATOR
Intervention: Tablet PC-based dementia training (control)
Number of subjects: 32
Study 33002745 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulator
Number of subjects: 60
Study 33002745 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted teaching
Number of subjects: 60
Study 33002745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 60
Study 33782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic whole-body cryotherapy (10 sessions, 3-min at -110 °C)
Number of subjects: 35
Study 33782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic whole-body cryotherapy
Number of subjects: 35
Study 33782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of whole-body cryotherapy
Number of subjects: 35
Study 32535135 — intervention group
Group type: COMPARATOR
Intervention: Baked Egg (BE) therapy
Number of subjects: 50
Study 32535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy (OIT)
Number of subjects: 50
Study 32535135 — intervention group
Group type: COMPARATOR
Intervention: Baked Egg (BE) therapy (comparator group)
Number of subjects: 50
Study 34836662 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy (SGT) with gastric juice PCR
Number of subjects: 182
Study 34836662 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-based standard triple therapy (STT)
Number of subjects: 182
Study 34836662 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy (SGT)
Number of subjects: 182
Study 32583392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle biopsy (FNB)
Number of subjects: 18
Study 32583392 — intervention group
Group type: COMPARATOR
Intervention: Fine-needle aspiration (FNA)
Number of subjects: 18
Study 32583392 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-facing bevel FNB needles
Number of subjects: 18
Study 32583392 — intervention group
Group type: COMPARATOR
Intervention: Reverse bevel FNB needle
Number of subjects: 18
Study 34893487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid only
Number of subjects: 35
Study 34893487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with VCM
Number of subjects: 35
Study 34893487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 35
Study 32382114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 48
Study 32382114 — intervention group
Group type: COMPARATOR
Intervention: Rescue dexamethasone after hydrocortisone therapy
Number of subjects: 48
Study 36147331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis (0, 10, or 25 mg Δ9‐THC)
Number of subjects: 32
Study 36147331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (0, 10, or 25 mg Δ9‐THC)
Number of subjects: 32
Study 36147331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target BAC of 0.05%)
Number of subjects: 32
Study 36147331 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (target BAC of 0.08%)
Number of subjects: 32
Study 36147331 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 32
Study 32931024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS)
Number of subjects: 200
Study 32931024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HIPEC)
Number of subjects: 200
Study 33555943 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 26
Study 33555943 — intervention group
Group type: COMPARATOR
Intervention: Concentric training
Number of subjects: 26
Study 33555943 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 26
Study 36083855 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (LTRA), specifically 10 mg of montelukast orally daily for 8 weeks.
Number of subjects: 40
Study 36083855 — intervention group
Group type: COMPARATOR
Intervention: Observation group (control).
Number of subjects: 40
Study 33284719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenpyr‐diethyl (50 g a.i. ha‐1) applied on soybean plants
Number of subjects: 0
Study 33284719 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32249668 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility Boot Camp‐Cognitive (ABC‐C)
Number of subjects: 46
Study 32249668 — intervention group
Group type: COMPARATOR
Intervention: Education interventions
Number of subjects: 46
Study 36050815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 1500
Study 36050815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 36219918 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic-biofeedback-assisted pelvic floor muscle training (BAPFMT) combined with neuromuscular electrical stimulation (NMES) of the rectus abdominis
Number of subjects: 66
Study 36219918 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) of the rectus abdominis alone
Number of subjects: 66
Study 32277701 — intervention group
Group type: EXPERIMENTAL
Intervention: Factory‐impregnated permethrin clothing
Number of subjects: 82
Study 32277701 — intervention group
Group type: COMPARATOR
Intervention: Sham‐treated clothing
Number of subjects: 82
Study 33130463 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH My Breath Program (CMB)
Number of subjects: 1400000
Study 32916135 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker strategy group
Number of subjects: 301
Study 32916135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 32916135 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker strategy group (per-protocol population)
Number of subjects: 301
Study 32916135 — intervention group
Group type: COMPARATOR
Intervention: Control group (per-protocol population)
Number of subjects: 301
Study 32916135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study 34935103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 166
Study 34935103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 34307140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy group (sustained-release fluorouracil implants after standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Number of subjects: 122
Study 34307140 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Number of subjects: 122
Study 34307140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy group
Number of subjects: 122
Study 34307140 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 34307140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 35442534 — intervention group
Group type: EXPERIMENTAL
Intervention: Online teaching video and case-based discussion (CBD), n=30
Number of subjects: 60
Study 35442534 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based teaching, n=30
Number of subjects: 60
Study 34133479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban combined with ozagrel (n=113)
Number of subjects: 337
Study 34133479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (n=110)
Number of subjects: 337
Study 34133479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozagrel (n=114)
Number of subjects: 337
Study 32813899 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (LE) after neoadjuvant radiochemotherapy (RCT)
Number of subjects: 110
Study 33397287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5 mg/kg bolus over 5 min followed by 1.5 mg/kg/h infusion)
Number of subjects: 71
Study 33397287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 71
Study 34708441 — intervention group
Group type: EXPERIMENTAL
Intervention: MINST+EMD
Number of subjects: 36
Study 34708441 — intervention group
Group type: COMPARATOR
Intervention: MINST
Number of subjects: 36
Study 33588086 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fibre shoe‐stiffening inserts
Number of subjects: 100
Study 33588086 — intervention group
Group type: COMPARATOR
Intervention: Sham inserts
Number of subjects: 100
Study 32000753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (40μm)
Number of subjects: 64
Study 32000753 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (25μm)
Number of subjects: 64
Study 32000753 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol (14μm)
Number of subjects: 64
Study 32000753 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all three powders
Number of subjects: 64
Study 35060676 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group in Stage I and Stage II of the adaptive two-stage design (ATD)
Number of subjects: 0
Study 35060676 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm in Stage II if propensity score distributions are comparable
Number of subjects: 0
Study 35060676 — intervention group
Group type: COMPARATOR
Intervention: Randomized stage II if propensity score distributions are not comparable
Number of subjects: 0
Study 35060676 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive two-stage design (ATD)
Number of subjects: 0
Study 35608017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral minocycline 100 mg per day plus NBUVB phototherapy
Number of subjects: 14
Study 35608017 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus NBUVB
Number of subjects: 14
Study 33463408 — intervention group
Group type: EXPERIMENTAL
Intervention: Egalitarian gender norms and beliefs
Number of subjects: 0
Study 33463408 — intervention group
Group type: COMPARATOR
Intervention: Traditional gender norms favoring males
Number of subjects: 0
Study 32957220 — intervention group
Group type: EXPERIMENTAL
Intervention: SU‐SE (10‐MDP based universal adhesive in self‐etching mode)
Number of subjects: 102
Study 32957220 — intervention group
Group type: EXPERIMENTAL
Intervention: SU‐ER (10‐MDP containing universal adhesive applied on etch‐and‐rinse mode)
Number of subjects: 102
Study 32957220 — intervention group
Group type: COMPARATOR
Intervention: SB (two‐step etch‐and‐rinse adhesive, 10‐MDP‐free control group)
Number of subjects: 102
Study 32957220 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX (2% chlorhexidine digluconate aqueous solution)
Number of subjects: 102
Study 32957220 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups with CHX pre‐treatment
Number of subjects: 102
Study 35698927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 45 mg
Number of subjects: 0
Study 35698927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 30 mg
Number of subjects: 0
Study 35698927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35698927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium (both dosages)
Number of subjects: 0
Study 34753411 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 55
Study 34753411 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 55
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative platelet elevation rate on the first day (PPER1)
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative platelet elevation rate on the third day (PPER3)
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Linear Model (GLM)
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Least Absolute Shrinkage and Selection Operator (LASSO)
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest Model (RFM)
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 483
Study 36157936 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Curve Analysis (DCA) and Clinical Impact Curve (CIC)
Number of subjects: 483
Study 34247588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐led telephonic case management
Number of subjects: 500
Study 34247588 — intervention group
Group type: COMPARATOR
Intervention: Specialty, outpatient palliative care
Number of subjects: 500
Study 33258788 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAN intervention (mobile texting and lay health supporters)
Number of subjects: 277
Study 33258788 — intervention group
Group type: COMPARATOR
Intervention: 686 Program alone (control)
Number of subjects: 277
Study 36122268 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic foot pain (CFP)
Number of subjects: 200
Study 36122268 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CFP)
Number of subjects: 200
Study 32385164 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSUVmax approach
Number of subjects: 596
Study 32385164 — intervention group
Group type: COMPARATOR
Intervention: Deauville score
Number of subjects: 596
Study 34936196 — intervention group
Group type: COMPARATOR
Intervention: Reattachment followed by placement of two external vertical grooves on the labial surface and restored with polyethylene fibers and hybrid composite (Ribbond group)
Number of subjects: 48
Study 34936196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattachment followed by two external vertical grooves and filled with fiber posts and composite (Fiber post group)
Number of subjects: 48
Study 34936196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattachment followed by circumferential chamfer at the fracture line and restored with composite (Chamfer group)
Number of subjects: 48
Study 34936196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 32005012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATO) 20 mg daily plus dexamethasone (DXM) regimen
Number of subjects: 60
Study 32005012 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (ATO) 20 mg daily
Number of subjects: 60
Study 35059244 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (aerobic and resistance exercise 3 times/week for 12 weeks)
Number of subjects: 228
Study 35059244 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 228
Study 35059244 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 228
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed drug use
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental drugs (iron folate)
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category A
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category B
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category C
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs from US-FDA category D or X
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level (primary education)
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level (secondary education)
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic illness
Number of subjects: 314
Study 33059613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigravida status
Number of subjects: 314
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Taopatch® devices
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint and Taopatch® devices together
Number of subjects: 18
Study 32744040 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatments)
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite alone
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Taopatch® devices alone
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite and Taopatch® devices used alone
Number of subjects: 18
Study 32744040 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tests (sEMG, kinesiography, squat jump, handgrip test)
Number of subjects: 18
Study 34348347 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week combined endurance, resistance, and balance exercise training
Number of subjects: 30
Study 35716850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 40